Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies
- PMID: 20734400
- DOI: 10.1002/pbc.22664
Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies
Abstract
Background: To analyze the impact of mediastinal irradiation on the incidence of cardiac late effects in long-term survivors of pediatric Hodgkin disease (HD).
Methods: The study cohort comprised 1,132 survivors of HD who received treatment before 18 years of age in consecutive trials between 1978 and 1995. They had maintained remission without secondary malignancy for 3.1-29.4 years. The cumulative doxorubicin dose was uniformly 160 mg/m(2), the mediastinal radiation dose (MedRD) was 36, 30, 25, 20, or 0 Gy. Follow-up questionnaires complemented by additional contacts served to collect information on late effects from patients and physicians. A central expert panel reviewed all reported cardiac abnormalities.
Results: By October 2008, cardiac diseases (CD) had been diagnosed in 50 of 1,132 patients aged 15.0-41.7 (median 32.2) years. The interval since HD therapy was 3.0-28.2 (median 19.5) years. Valvular defects were diagnosed most frequently, followed by coronary artery diseases, cardiomyopathies, conduction disorders, and pericardial abnormalities. The cumulative incidence of CD after 25 years was highest in the MedRD-36 group (21%) decreasing to 10%, 6%, 5%, and 3% in the lower MedRD groups (P < 0.001). Multivariate Cox analysis of several putative risk factors showed MedRD to be the only significant variable predicting for CD-free survival (P = 0.0025).
Conclusions: Our results indicate that lower MedRDs are less cardiotoxic. Consequently, reduction of cardiac late effects may be expected with the lower radiation doses used in current HD protocols. Longer follow-up is needed to confirm the present results.
Similar articles
-
Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.J Clin Oncol. 2006 Dec 20;24(36):5735-41. doi: 10.1200/JCO.2006.05.6879. J Clin Oncol. 2006. PMID: 17179107
-
Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.Cancer. 2000 May 1;88(9):2142-8. Cancer. 2000. PMID: 10813727
-
Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.Haematologica. 1999 Oct;84(10):917-23. Haematologica. 1999. PMID: 10509040 Clinical Trial.
-
Pediatric Hodgkin's disease: treatment in the late 1990s.Ann Oncol. 1998;9 Suppl 5:S115-9. doi: 10.1093/annonc/9.suppl_5.s115. Ann Oncol. 1998. PMID: 9926249 Review.
-
[Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].Sangre (Barc). 1998 Jun;43(3):179-84. Sangre (Barc). 1998. PMID: 9741222 Review. Spanish.
Cited by
-
Pulmonary lesions in early response assessment in pediatric Hodgkin lymphoma: prevalence and possible implications for initial staging.Pediatr Radiol. 2024 May;54(5):725-736. doi: 10.1007/s00247-024-05859-y. Epub 2024 Jan 31. Pediatr Radiol. 2024. PMID: 38296856 Free PMC article.
-
Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children.JAMA Netw Open. 2024 Jan 2;7(1):e2351062. doi: 10.1001/jamanetworkopen.2023.51062. JAMA Netw Open. 2024. PMID: 38241048 Free PMC article. Clinical Trial.
-
Prevention of activated brown adipose tissue on 18F-FDG-PET scans of young lymphoma patients: results of an ancillary study within the EuroNet-PHL-C2 trial.Sci Rep. 2023 Dec 11;13(1):21944. doi: 10.1038/s41598-023-48871-2. Sci Rep. 2023. PMID: 38081864 Free PMC article. Clinical Trial.
-
Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future.Front Cardiovasc Med. 2023 Aug 30;10:1243531. doi: 10.3389/fcvm.2023.1243531. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37711551 Free PMC article. Review.
-
Dosiomics-Based Prediction of Radiation-Induced Valvulopathy after Childhood Cancer.Cancers (Basel). 2023 Jun 8;15(12):3107. doi: 10.3390/cancers15123107. Cancers (Basel). 2023. PMID: 37370717 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical